ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT ID: NCT01208090
Last Updated: 2025-03-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
326 participants
INTERVENTIONAL
2010-10-31
2012-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ACT-128800 in Psoriasis
NCT00852670
Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis
NCT05725057
A Phase II Clinical Study of AC-201 Tablets in Subjects With Plaque Psoriasis
NCT06972888
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115
A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis
NCT02173301
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Investigational drug - Dose 1
ACT-128800
ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
Investigational drug - Dose 2
ACT-128800
ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
Matching placebo
Placebo
ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ACT-128800
ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
Placebo
ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Systemic or topical treatments for psoriasis other than emollients. Ongoing bacterial, viral or fungal infections.
History or presence of malignancy.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Actelion
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Actelion Pharmaceuticals
Role: STUDY_DIRECTOR
Actelion
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Investigative Site 1006
Feldkirch, , Austria
Clinical Investigative Site 1002
Graz, , Austria
Clinical Investigative Site 1004
Sankt Pölten, , Austria
Clinical Investigative Site 1007
Vienna, , Austria
Clinical Investigative Site 1001
Vienna, , Austria
Clinical Investigative Site 1103
Brussels, , Belgium
Clinical Investigative Site 1102
Edegem, , Belgium
Clinical Investigative Site 1101
Liège, , Belgium
Clinical Investigative Site 1205
Pleven, , Bulgaria
Clinical Investigative Site 1204
Plovdiv, , Bulgaria
Clinical Investigative Site 1202
Sofia, , Bulgaria
Clinical Investigative Site 1201
Sofia, , Bulgaria
Clinical Investigative Site 1203
Sofia, , Bulgaria
Clinical Investigative Site 1206
Stara Zagora, , Bulgaria
Clinical Investigative Site 1402
Hradec Králové, , Czechia
Clinical Investigative Site 1405
Nový Jičín, , Czechia
Clinical Investigative Site 1406
Pardubice, , Czechia
Clinical Investigative Site 1401
Prague, , Czechia
Clinical Investigative Site 1502
Copenhagen, , Denmark
Clinical Investigative Site 1504
Roskilde, , Denmark
Clinical Investigative Site 1704
Bordeaux, , France
Clinical Investigative Site 1701
Nice, , France
Clinical Investigative Site 1707
Paris, , France
Clinical Investigative Site 1710
Paris, , France
Clinical Investigative Site 1705
Pierre-Bénite, , France
Clinical Investigative Site 1703
Poitiers, , France
Clinical Investigative Site 1702
Saint-Etienne, , France
Clinical Investigative Site 2002
Budapest, , Hungary
Clinical Investigative Site 2001
Debrecen, , Hungary
Clinical Investigative Site 2006
Miskolc, , Hungary
Clinical Investigative Site 2005
Pécs, , Hungary
Clinical Investigative Site 2003
Szeged, , Hungary
Clinical Investigative Site 2004
Veszprém, , Hungary
Clinical Investigative Site 2315
Ancona, , Italy
Clinical Investigative Site 2303
Bergamo, , Italy
Clinical Investigative Site 2307
Bologna, , Italy
Clinical Investigative Site 2317
Genova, , Italy
Clinical Investigative Site 2309
L’Aquila, , Italy
Clinical Investigative Site 2310
Pisa, , Italy
Clinical Investigative Site 2304
Roma, , Italy
Clinical Investigative Site 2316
Rome, , Italy
Clinical Investigative Site 3801
Vilnius, , Lithuania
Clinical Investigative Site 2608
Bucharest, , Romania
Clinical Investigative Site 2601
Bucharest, , Romania
Clinical Investigative Site 2604
Cluj-Napoca, , Romania
Clinical Investigative Site 2603
Iași, , Romania
Clinical Investigative Site 2606
Oradea, , Romania
Clinical Investigative Site 2607
Sibiu, , Romania
Clinical Investigative Site 2605
Târgu Mureş, , Romania
Clinical Investigative Site 2602
Timișoara, , Romania
Clinical Investigative Site 3410
Krasnodar, , Russia
Clinical Investigative Site 2704
Banská Bystrica, , Slovakia
Clinical Investigative Site 2705
Kosice-Saca, , Slovakia
Clinical Investigative Site 2701
Košice, , Slovakia
Clinical Investigative Site 2708
Trnava, , Slovakia
Clinical Investigative Site 2901
Barcelona, , Spain
Clinical Investigative Site 2907
Las Palmas de Gran Canaria, , Spain
Clinical Investigative Site 2902
Madrid, , Spain
Clinical Investigative Site 2904
Madrid, , Spain
Clinical Investigative Site 3001
Stockholm, , Sweden
Clinical Investigative Site 3006
Umeå, , Sweden
Clinical Investigative Site 3101
Lausanne, , Switzerland
Clinical Investigative Site 3103
Zurich, , Switzerland
Clinical Investigative Site 3512
Poltava, , Ukraine
Clinical Investigative Site 3514
Zaporizhia, , Ukraine
Clinical Investigative Site 3306
Dundee, , United Kingdom
Clinical Investigative Site 3304
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Vaclavkova A, Chimenti S, Arenberger P, Hollo P, Sator PG, Burcklen M, Stefani M, D'Ambrosio D. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014 Dec 6;384(9959):2036-45. doi: 10.1016/S0140-6736(14)60803-5. Epub 2014 Aug 10.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AC-058A201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.